The Journal of Urology
Volume 183, Issue 2 , Pages 634-640, February 2010

Does Neoadjuvant Hormonal Therapy Improve Urinary Function When Given to Men With Large Prostates Undergoing Prostate Brachytherapy?

  • Nelson N. Stone

      Affiliations

    • Corresponding Author InformationCorrespondence: 21 Timber Trail, Suffern, New York 10901 (telephone: 212-535-0755; FAX: 845-362-8561)
    • Financial interest and/or other relationship with Prologics, Nihon MediPhysics, Iso Aid and PCED.
  • ,
  • David T. Marshall

      Affiliations

    • Current address: Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina.
  • ,
  • Jonathan J. Stone
  • ,
  • Jamie A. Cesaretti

      Affiliations

    • Financial interest and/or other relationship with C. R. Bard.
  • ,
  • Richard G. Stock

Departments of Radiation Oncology (DTM, JJS, JAC) and Urology (NNS), Mount Sinai School of Medicine, New York, New York

Received 27 May 2009 published online 16 December 2009.

Purpose

We evaluated the effect of neoadjuvant hormonal therapy on urinary function in men with a prostate volume of 50 cc or greater undergoing prostate brachytherapy.

Materials and Methods

A total of 395 men with 50 cc or greater glands were treated with 3 months of neoadjuvant hormonal therapy (204) or implantation alone (191). Urinary function was assessed by the International Prostate Symptom Score, the urinary retention incidence and subsequent transurethral prostate resection.

Results

Median patient age was 67 years and median followup was 6 years. Mean prostate volume in neoadjuvant hormonal therapy cases was 72.9 cc, which decreased to 54.3 cc after 3 months (p <0.001). Mean prostate volume in cases without hormonal therapy was 60.6 cc (p <0.001). Urinary retention occurred in 16 of 191 men (8.4%) without vs 25 of 204 (12.3%) with hormonal therapy (p = 0.207). The median duration of urinary retention was 42 days (range 2 to 243). There were no significant associations of urinary retention with prostate size, prostate or urethral dose, or pre-implantation International Prostate Symptom Score. Of patients without hormonal therapy retention occurred in 3 of 12 (25%) with a pre-implantation International Prostate Symptom Score of 15 or greater and in 13 of 168 (7.7%) with a score of less than 15 (OR 4.0, 95% CI 1–16, p = 0.04). In contrast, there was no difference in the retention rate in patients with hormonal therapy with an initial score of 15 or greater vs less than 15 (2 of 25 or 8% vs 11 of 102 or 10.8%, p = 0.614). Transurethral prostate resection was done in 11 of 191 men (5.8%) without vs 12 of 204 (5.9%) with hormonal therapy (p = 0.958). There was no difference in biochemical failure in the 2 groups.

Conclusions

Neoadjuvant hormonal therapy has its greatest benefit in patients receiving brachytherapy who have a large prostate and an International Prostate Symptom Score of 15 or greater.

Key Words: prostate, urinary retention, brachytherapy, agonists, organ size

Abbreviations and Acronyms: HT, hormone therapy, I-PSS, International Prostate Symptom Score, NHT, neoadjuvant HT, PSA, prostate specific antigen, PV, prostate volume, TURP, transurethral resection of the prostate, UD30, dose to 30% of urethral volume

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received Mount Sinai School of Medicine institutional review board approval.

PII: S0022-5347(09)02625-1

doi:10.1016/j.juro.2009.09.084

The Journal of Urology
Volume 183, Issue 2 , Pages 634-640, February 2010